查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1519762

2024-2032年按药物类别、给药途径、配销通路和地区分類的降血脂药物市场报告

Antihyperlipidemic Drugs Market Report by Drug Class, Route of Administration, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球降血脂药物市场规模达126亿美元。

降血脂药物有助于降低血清胆固醇和血液中各种脂质的水平。它们可以与不同的药物一起服用，以控制高胆固醇并降低某些疾病的风险。目前，它们的不同类别在全球范围内都有提供，可以根据患者的胆固醇状况、潜在疾病和其他因素进行分类。一些常用的降血脂药物包括他汀类药物、降血脂复方药物、胆汁酸螯合剂、胆固醇吸收抑制剂、纤维酸衍生物和 PCSK9 抑制剂。

降血脂药物市场趋势：

由于久坐的生活方式、尼古丁成瘾和高脂肪食物的摄入，高血脂症的盛行率不断上升，这是促进降血脂药物需求的关键因素之一。此外，高血脂症会增加冠状动脉疾病（CAD）的风险，而冠状动脉疾病是全世界成年人最常见的死亡原因。因此，越来越需要这些药物来降低高水平的低密度脂蛋白（LDL）胆固醇和三酸甘油酯，同时增加低水平的高密度脂蛋白（HDL）胆固醇。除此之外，它们也用于治疗患有高胆固醇水平和各种脂质疾病的儿童。此外，儿科族群中遗传性和后天性脂质和脂蛋白代谢疾病数量的激增正在积极影响对降血脂药物的需求，以降低住院率和过早死亡率。此外，新药和先进药物的批准正在为市场创造良好的前景。除此之外，世界各地的药物化学家正在设计、合成和评估这些药物的各种新分子，预计这将有助于市场的成长。

本报告回答的关键问题

  • 2023年全球降血脂药物市场规模有多大？
  • 2024-2032年全球降血脂药物市场的预期成长率是多少？
  • 推动全球降血脂药物市场的关键因素是什么？
  • COVID-19对全球降血脂药物市场有何影响？
  • 全球降血脂药物市场按药物类别划分是怎样的？
  • 全球降血脂药物市场按配销通路划分是怎样的？
  • 全球降血脂药物市场的重点区域有哪些？
  • 全球降血脂药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球降血脂药物市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依药物类别

  • 他汀类药物
    • 市场走向
    • 市场预测
  • 胆汁酸螯合剂
    • 市场走向
    • 市场预测
  • 胆固醇吸收抑制剂
    • 市场走向
    • 市场预测
  • 纤维酸衍生物
    • 市场走向
    • 市场预测
  • PCSK9 抑制剂
    • 市场走向
    • 市场预测
  • 组合
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依管理途径

  • 口服
    • 市场走向
    • 市场预测
  • 静脉
    • 市场走向
    • 市场预测

第 8 章：市场区隔：按配销通路

  • 医院药房
    • 市场走向
    • 市场预测
  • 零售店
    • 市场走向
    • 市场预测
  • 网路零售商
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Amgen Inc.
    • AstraZeneca plc
    • Daiichi Sankyo Company Limited
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112024A5622

The global antihyperlipidemic drugs market size reached US$ 12.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.2 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.

Antihyperlipidemic drugs help lower serum levels of cholesterol and various lipids in the blood. They can be taken with different medications to control high cholesterol and reduce the risk of certain medical conditions. At present, their different classes are available worldwide, which can be given based on the patient's cholesterol profile, underlying disease, and other factors. Some of the commonly available antihyperlipidemic drugs include statins, antihyperlipidemic combinations, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and PCSK9 inhibitors.

Antihyperlipidemic Drugs Market Trends:

The growing prevalence of hyperlipidemia on account of sedentary lifestyles, nicotine addiction, and high consumption of fatty foods represents one of the key factors catalyzing the demand for antihyperlipidemic drugs. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is the most common cause of death among adults worldwide. As a result, there is a rise in the need for these drugs to reduce the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides while increasing the low levels of high-density lipoprotein (HDL) cholesterol. Apart from this, they are used to treat children with high cholesterol levels and various lipid disorders. In addition, a surge in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population is positively influencing the need for antihyperlipidemic drugs to reduce the rates of hospitalization and premature deaths. Furthermore, the approval of new and advanced drugs is creating a favorable outlook for the market. Besides this, medicinal chemists around the world are designing, synthesizing, and evaluating a variety of new molecules for these drugs, which is anticipated to contribute to the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antihyperlipidemic drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, route of administration and distribution channel.

Breakup by Drug Class:

Statins

Bile Acid Sequestrants

Cholesterol Absorption Inhibitors

Fibric Acid Derivatives

PCSK9 Inhibitors

Combination

Others

Breakup by Route of Administration:

Oral

Intravenous

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Stores

Online Retailers

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.

Key Questions Answered in This Report

  • 1. What was the size of the global antihyperlipidemic drugs market in 2023?
  • 2. What is the expected growth rate of the global antihyperlipidemic drugs market during 2024-2032?
  • 3. What are the key factors driving the global antihyperlipidemic drugs market?
  • 4. What has been the impact of COVID-19 on the global antihyperlipidemic drugs market?
  • 5. What is the breakup of the global antihyperlipidemic drugs market based on the drug class?
  • 6. What is the breakup of the global antihyperlipidemic drugs market based on the distribution channel?
  • 7. What are the key regions in the global antihyperlipidemic drugs market?
  • 8. Who are the key players/companies in the global antihyperlipidemic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antihyperlipidemic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Statins
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bile Acid Sequestrants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cholesterol Absorption Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Fibric Acid Derivatives
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 PCSK9 Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Combination
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intravenous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Stores
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Retailers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Daiichi Sankyo Company Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Merck & Co. Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Novartis AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Sanofi S.A
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials

List of Figures

  • Figure 1: Global: Antihyperlipidemic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Antihyperlipidemic Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Antihyperlipidemic Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 5: Global: Antihyperlipidemic Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Antihyperlipidemic Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Antihyperlipidemic Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Antihyperlipidemic Drugs (Statins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Antihyperlipidemic Drugs (Statins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Antihyperlipidemic Drugs (Combination) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Antihyperlipidemic Drugs (Combination) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Antihyperlipidemic Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Antihyperlipidemic Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Antihyperlipidemic Drugs (Intravenous) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Antihyperlipidemic Drugs (Intravenous) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Antihyperlipidemic Drugs (Retail Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Antihyperlipidemic Drugs (Retail Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Antihyperlipidemic Drugs (Online Retailers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Antihyperlipidemic Drugs (Online Retailers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia-Pacific: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia-Pacific: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Antihyperlipidemic Drugs Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Antihyperlipidemic Drugs Industry: SWOT Analysis
  • Figure 82: Global: Antihyperlipidemic Drugs Industry: Value Chain Analysis
  • Figure 83: Global: Antihyperlipidemic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antihyperlipidemic Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Antihyperlipidemic Drugs Market: Competitive Structure
  • Table 7: Global: Antihyperlipidemic Drugs Market: Key Players